EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes

Chanmi Park iD, Dong-Sook Kim, Inmyung Song iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0319674 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Chanmi Park und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Center, Korea University Guro Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Drugs, Generic, Drug Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare of Korea, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prices of generic drugs in general are known to be higher in Korea than in other countries. However, it remains unknown whether the price levels of generic drugs in Korea relative to other countries can differ by therapeutic class. Therefore, this study compared the prices of generic drugs in four commonly used drug classes in Korea with those in other high-income countries.

Methods

Using IQVIA’s Pricing Insight data from 2018 to 2022, we calculated the Laspeyres price index for generic drugs in four therapeutic classes (antidiabetic drugs, lipid-modifying agents, antihypertensive drugs, and antibiotics). We selected eight high-income countries, such as Canada, France, Germany, Italy, Japan, Switzerland, the United Kingdom, and the United States, for comparison and Korea as the base country. Price to chemist was used and the currency conversion was based on the exchange rate and the purchasing power parity.

Results

Prices of generic drugs are lower in all of comparison countries combined than in Korea for lipid-modifying drugs and antihypertensive drugs. For these two drug classes, all countries but the U.S. have the index lower than one. The index for antidiabetic drugs was less than one in all countries except for Canada and the U.S. For antibiotics, all countries but France, Italy, and Japan have the index that is greater than one. Furthermore, the price index for generic antibiotics increased from 2018 to 2022 in all countries but Canada and Japan.

Conclusion

The prices of generic drugs are higher in Korea than in other high-income countries for lipid-modifying agents and antihypertensive drugs. The prices of generic antibiotics are higher in many comparison countries and have further increased from 2018 to 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericDrug CostsRepublic of KoreaHumansAntihypertensive AgentsDeveloped CountriesHypoglycemic AgentsAnti-Bacterial AgentsCanadaUnited StatesJapanUnited KingdomItalyFranceGermany

Substanzen

Drugs, GenericAntihypertensive AgentsHypoglycemic AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Biomedical Research Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • College of Nursing and Health, Kongju National University, Gongju, Republic of Korea.

ORCID-Profile: Chanmi Park, Inmyung Song

Förderung

  • Ministry of Health and Welfare of Korea
  • Ministry of Health and Welfare

Zitieren

APA

Park, C., Kim, D. S., & Song, I. (2025). Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes. PLOS ONE. https://doi.org/10.1371/journal.pone.0319674

Vancouver

Park C, Kim DS, Song I. Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes. PLOS ONE. 2025. doi:10.1371/journal.pone.0319674

BibTeX
@article{Park2025,
  author = {Park, Chanmi and Kim, Dong-Sook and Song, Inmyung},
  title = {Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0319674}
}
Kostenlos starten →